What does it mean to put new hepatitis C drugs on a list of essential medicines?
Interfaculty Initiative in Health Policy, Harvard University, Cambridge, MA 02138, USA jurrutia@fas.harvard.edu.
Julian
J
Urrutia
Interfaculty Initiative in Health Policy, Harvard University, Cambridge, MA 02138, USA.
Thalia
T
Porteny
Department of Global Health and Population, Harvard T H Chan School of Public Health, Boston, MA, USA.
Norman
N
Daniels
D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use; D002219:Carbamates / Q000191:economics* / Q000627:therapeutic use; D016527:Drug Costs; D018954:Drugs, Essential / Q000191:economics* / Q000627:therapeutic use; D006292:Health Priorities; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006576:Heterocyclic Compounds, 4 or More Rings / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D000069474:Sofosbuvir / Q000191:economics* / Q000627:therapeutic use; D014944:World Health Organization; D001562:Benzimidazoles; D001578:Benzopyrans
D000998:Antiviral Agents; D002219:Carbamates; D018954:Drugs, Essential; D006576:Heterocyclic Compounds, 4 or More Rings; D000069474:Sofosbuvir; C000604171:velpatasvir; D001562:Benzimidazoles; D001578:Benzopyrans